Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to Capecitabine Based Adjuvant Chemotherapy in Colon Cancer Treatment

NCT00126867 is registered in ClinicalTrials.gov with AHS Cancer Control Alberta as lead sponsor.

NCT NCT00126867
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00126867 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to Capecitabine Based Adjuvant Chemotherapy in Colon Cancer Treatment
Lead sponsor
AHS Cancer Control Alberta
Phase
Observational
Overall status
Terminated
Start date
May 31, 2005
Completion date
April 11, 2019
Enrollment
29 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colon cancer